Research goals: Metabolic & Weight Description Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine , The Lancet , and Nature Medicine , including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants
No waiting rooms, no commute
For a minority, residual sensitivity persists but becomes their new normal
Perfect for Travel Stay consistent with your wellness routine, even on the go
Because Melanotan II works within the broader melanocortin system, MC1R variation may influence related signaling, though its main well-known role remains pigmentation
10.3389/fnut.2024.1421386 17 ChenW